Oragenics, Inc. Announces Closing of Public Offering

SARASOTA, Fla., Sept. 5, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on the development of unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced offering of 3,078,378 shares of its common stock and pre-funded warrants to purchase up to 5,028,206 shares of its common stock at an offering price of $0.55 per share and $0.549 per pre-funded warrant. Immediately following the closing of the offering, the Company will have outstanding 8,659,071 shares of its common stock and pre-funded warrants to purchase up to 5,028,206 shares of its common stock. The exercise price of each pre-funded warrant is $0.001.

The gross proceeds from the offering are approximately $4.45 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the proceeds from the offering to fund further development of its ONP-002 product candidate and for general corporate and working capital purposes.